Heart failure is often framed as a problem of pump function. It occurs when the heart can’t contract forcefully enough or relax properly to fill with blood.Underlying both of those dysfunctions is a cellular process that researchers are still working to interrupt .
Cardiac fibroblasts are central to that process. When they activate, they reshape the architecture of the heart in ways that accelerate dysfunction, provoke arrhythmias, and make recovery progressively harder to achieve. Here’s what you need to know.
What Cardiac Fibroblasts Do Under Normal Conditions
In a healthy heart, cardiac fibroblasts function as the myocardium’s maintenance cells . They synthesize and degrade extracellular matrix (ECM) proteins to maintain the integrity of the myocardial scaffold. They also maintain the structural environment that allows cardiomyocytes to contract in a coordinated and efficient manner .
Under normal conditions, ECM production and degradation are tightly balanced. Fibroblasts support function without dominating it. But that balance breaks down under stress.
The Transition to Myofibroblasts
After myocardial injury, biochemical signaling triggers a fundamental change in cardiac fibroblast behavior . They differentiate into myofibroblasts, a more contractile, secretory, and far more aggressive cell type.
Myofibroblasts produce collagen at a rate that exceeds the heart’s capacity for degradation. The result is excess ECM deposition, or fibrosis. That fibrosis replaces functional myocardial tissue with stiff, inert scar. And the transformation is largely irreversible with treatments currently available.
The problem is not the initial response. Some degree of fibrosis after injury is protective because it prevents the ventricle from rupturing in the acute phase. However, the damage accumulates when myofibroblast activation persists long after the original injury has resolved.
How Fibrosis Drives Heart Failure
Excess collagen deposition affects nearly every aspect of cardiac function. Diastolic dysfunction is the most direct result.
A fibrotic myocardium becomes increasingly stiff , and a stiff ventricle cannot relax and fill efficiently during diastole. This is the defining pathophysiology of heart failure with preserved ejection fraction (HFpEF).
HFpEF is a form of heart failure in which the left ventricle contracts normally but cannot fill properly at normal pressures. HFpEF now accounts for roughly half of all heart failure cases, and fibrosis is one of its primary drivers.
Chamber Remodeling and Dilation
When fibrosis is patchy rather than diffuse, the non-fibrotic regions of the ventricle bear a disproportionate mechanical load. Over time, those regions stretch, thin, and dilate over time. Then the geometry of the chamber changes, and contractile efficiency falls.
This remodeling process becomes self-reinforcing: dilation increases wall stress, which drives further fibroblast activation, which produces more fibrosis.
Arrhythmias arise because fibrosis disrupts the heart’s electrical architecture. Collagen deposits between cardiomyocytes disrupt gap junctions, which allow coordinated electrical conduction. Signals slow down, fragment, and then find abnormal pathways. The result is an electrical substrate highly favorable to re-entrant arrhythmias, which worsen symptoms and independently increase mortality .
Cardiomyocyte dysfunction is compounded by the fibrotic response environment itself. Cardiomyocytes surrounded by excess ECM receive less oxygen, face altered mechanical forces, and lose the direct cell-to-cell communication that coordinates contraction. As a result, the structural support that fibroblasts are meant to provide becomes a constraint.
The Inflammatory Dimension
Activated cardiac fibroblasts are not passive scar-formers. They are highly active secretory cells that release pro-inflammatory cytokines (i.e., TGF-β, IL-6, and TNF-α) into the myocardial environment. This cytokine signaling recruits immune cells, sustains inflammation, and creates a chronic inflammatory state within the heart muscle that accelerates cardiomyocyte death and promotes further fibroblast activation.
One pathway under active investigation is the MYC–CXCL1–CXCR2 axis. In this signaling cascade, the transcription factor MYC drives fibroblasts to produce CXCL1, a chemokine that binds the CXCR2 receptor on cardiomyocytes and disrupts their function directly. In this way , activated fibroblasts actively signal to muscle cells in ways that impair contraction and promote cell death.
A Self-Perpetuating Cycle in Heart Failure Progression
One of the most clinically significant features of cardiac fibrosis is its tendency to become self-sustaining. Myocardial stiffness itself acts as a mechanical stimulus for further fibroblast activation.
Elevated wall stress signals fibroblasts to produce more collagen. More collagen leads to greater stiffness, which drives even more fibroblast activation.
This cycle doesn’t require ongoing injury to continue. In fact, it can persist and progress in the absence of any new insult. Heart failure may continue to worsen even when the underlying disease progression appears stable by conventional measures.
Exosomes, MicroRNAs, and the Broader Signaling Network
Cardiac fibroblasts communicate beyond direct cell contact; they release exosomes into the myocardial environment. These exosomes(small membrane-bound vesicles that carry proteins, lipids, and microRNAs) are taken up by adjacent cardiomyocytes, where their miRNA cargo alters gene expression to promote cardiac hypertrophy and impair contractile function.
This paracrine signaling adds another layer of complexity to fibroblast-driven heart failure progression. It means that fibroblast activation reaches into the gene expression programs of the very muscle cells the heart depends on to function.
Specific miRNAs carried in fibroblast-derived exosomes are now being studied as biomarkers of fibrotic activity and as potential therapeutic targets. Patients interested in emerging fibrosis research should speak with their healthcare provider for more information.
Why This Matters for Treatment
Current heart failure therapies, including diuretics, neurohormonal blockade, and device therapy, address the downstream consequences of fibrosis without touching the fibrotic process itself.
These therapies can reduce congestion, lower wall stress, and slow remodeling at the organ level. But they don’t reverse the collagen already deposited, halt myofibroblast activity, or interrupt the signaling cascades that drive ongoing fibrosis progression.
Anti-fibrotic strategies under investigation include TGF-β pathway inhibitors, targeted disruption of the MYC–CXCL1–CXCR2 axis, and approaches that exploit fibroblast-derived exosome biology to deliver therapeutic miRNAs directly to cardiac tissue. However, none of these approaches has yet entered standard clinical practice .
The mechanistic understanding driving these efforts is substantially more advanced than it was a decade ago. The goal is not to eliminate all fibrosis entirely, since some degree of structural repair after injury is necessary. The goal is to stop the process before it becomes self-sustaining, and to eventually develop tools that can reverse what has already accumulated.
FAQs
Is cardiac fibrosis reversible?
In most cases, established fibrosis is not reversible with currently available treatments. Existing therapies can slow its progression and reduce the rate of new collagen deposition, but they cannot break down mature scar tissue already present in the myocardium.
How does fibrosis relate to HFpEF?
HFpEF is the form of heart failure most directly linked to myocardial fibrosis. Because the ventricle is stiff rather than weak, standard measures of contractile function appear normal even as the heart fails to fill and eject at appropriate pressures. Fibrosis is a cause of that stiffness and a marker of disease severity in HfpEF. It is also one reason why the condition has proven more difficult to treat than heart failure with reduced ejection fraction.
Can fibroblast activity be measured clinically?
There is currently no routine clinical test that quantifies fibroblast activation or fibrotic burden in real time. Cardiac MRI with late gadolinium enhancement can identify areas of established fibrosis, and circulating biomarkers such as soluble ST2 and galectin-3 indirectly reflect fibrotic activity. Research into fibroblast-derived miRNAs as blood-based biomarkers may eventually provide more precise tools for monitoring fibrotic progression and treatment response.
The Path Forward
Cardiac fibroblasts occupy a position in heart failure pathophysiology that their inconspicuous name doesn’t reflect. They don’t just scar injured tissue; they also remodel the entire myocardial environment and:
- signal to muscle cells through multiple pathways
- sustain inflammation
- create the electrical substrate for arrhythmias
- drive a self-perpetuating cycle of dysfunction that current therapies cannot fully interrupt.
Understanding their biology is not an academic exercise. It is the foundation on which the next generation of heart failure treatment will be built.
Visit the Nora Eccles Harrison Cardiovascular Research and Training Institute for the latest research on cardiac fibrosis, heart disease, and heart failure biology.
